|
DNA LandMarks
DNA LandMarks has grown to boast a state of the art molecular lab where our
dedicated team strive to offer our customers exceptional service.
Our affiliation with BPS has allowed us the resources to develop cutting
edge, high throughput technology. However our independence as a small, stand
alone operating unit allows us to be flexible and responsive to the needs of
each of our customers. You will find our service to be the very best in
accuracy, consistency and confidentiality.
Our genetic technologies are a perfect complement to conventional plant
breeding programs. Come and see how DNA LandMarks can help you mark your
success…
DNA LandMarks Inc
84 Richelieu street
Saint-Jean-sur-Richelieu, Quebec, Canada
Phone number: (450) 358-2621
Fax: (450) 358-1154
For all commercial inquiries, please contact:
Charles Pick, Business Development Manager
Extension: 123
Cell: (514) 771-5667
pickc@dnalandmarks.ca
Company Overview
diaDexus, Inc., a privately held biotechnology company, is focused on the
discovery, development, and commercialization of novel, patent protected
diagnostic and therapeutic products with high clinical value. diaDexus utilizes
genomics and bioinformatics to identify numerous disease-associated molecular
targets.
In July 2003, diaDexus received FDA clearance to
market the PLAC™ test as an aid in the prediction of coronary heart disease risk
(CHD). The PLAC™ test determines levels of Lp-PLA2 in the blood, which has been
shown to increase coronary heart disease risk, the leading cause of death in
America.
As one of the first companies to recognize the
potential of genomics to generate valuable diagnostics tests, the company has
filed patent applications on more than 5,000 molecular targets. diaDexus
currently has 13 potential novel diagnostic product candidates in preclinical
development and has conducted preclinical validation on five potential
therapeutic antibody targets. |
